CTOs on the Move

uniPHARM Wholesale Drugs

www.unipharm.com

 
uniPHARM Wholesale Drugs Ltd. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.unipharm.com
  • 2051 Van Dyke Pl
    Richmond, BC CAN V6V 1X6
  • Phone: 604.270.9745

Executives

Name Title Contact Details

Similar Companies

Banziger Systems

Banziger Systems is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Roha Food Colors

Roha Food Colors is a Trumbull, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Broadstep

CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...

Texas Road Pharmacy

Texas Road Pharmacy is a Monroe Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.